T

TransMedics

Ex-vivo organ perfusion platform

Principal Clinical Trial Manager

Full-Time
$151.5k - $215.7k+ Bonus + Equity
Expert
Bachelor's, Master's
Andover, MA, USA
In PersonTravel up to 25% of the time.
Biology & BiotechClinical Research Operations

About the job

Requirements
  • A BA/BS in Science, Life Sciences, or a relevant field is required.
  • Have 8–10 years of experience in pharmaceutical drug development, biotechnology, or CRO industries monitoring and managing clinical trials, or an equivalent combination of education and experience.
  • Have proven expertise in executing IRB/EC submissions and approvals.
Responsibilities
  • Lead pre- and post-market clinical trials for the FDA using effective organizational strategies, and review and present results using rigorous clinical procedures.
  • Create study-specific templates across all programs.
  • Manage the planning, implementation, and tracking of the clinical monitoring process with CRAs.
  • Oversee drafting annual and bi-annual pre- and post-market reports to the FDA in collaboration with the regulatory team.
  • Lead clinical site interactions, including assistance with IRB/EC applications, contract negotiations, enrollment tracking, clinical trial material and clinical supply requests, and issue resolution.
  • Own and manage trial start-up, conduct, and close-out activities according to industry and corporate standards.
  • Contribute expertise to preparing key clinical documents with other team members, including protocols, informed consent, amendments, CRFs, training materials, project plans, monitoring plans, data plans, statistical analysis plans, and summary reports.
  • Establish professional rapport and communicate frequently with investigational site personnel to keep studies on track.
  • Track internal metrics, timelines, and budgets.
  • Communicate trial status to the trial team.
  • Prepare and present trial-specific updates to management.
  • Oversee and participate in monitoring activities at clinical trial sites to ensure adherence to GCP and ICH guidelines, regulatory requirements, SOPs, and protocols, and take ownership of data completion and accuracy.
  • Interact with data management personnel to plan, monitor, and execute data analyses.
  • Support applications and technical files as needed.
  • Collaborate with project-specific committees such as DSMB and CEC.
  • Assist with preparation for investigators’ meetings.
  • Work with vendors as needed.
  • Perform other assigned or required TransMedics tasks and duties.
Desired Qualifications
  • A Master's in Science, Life Sciences, or a relevant field, or an equivalent combination of education and experience.
  • Experience in medical devices is strongly preferred.
  • A track record leading large, complex global clinical trials for medical device products in different phases of the product cycle.
  • Broad and deep knowledge of device clinical trial documentation requirements, including monitoring requirements, FDA regulations, and clinical trial operational aspects.
  • Experience complying with GCP, ICH, ISO, and FDA regulatory requirements.
  • Ability to identify operational issues and proactively recommend and implement strategies to resolve problems.
  • In-depth knowledge of adverse event investigation, analysis, and reporting procedures and standards.
  • Willingness to be held accountable for deliverables.
  • Highly organized and detail-oriented.
  • Experience interfacing with multiple vendors or contractors.
  • Ability to handle multiple projects and changing priorities.
  • Results-driven approach and sense of urgency.
  • Clear and concise verbal and written communication that fosters the timely flow of relevant information.
  • Strong initiative and positive attitude.
  • Ability to support and build collaborative relationships internally and externally.
  • Demonstrated ability to make timely decisions using sound judgment.
  • Experience with electronic data capture (EDC).
  • Experience in clinical budget planning and management.
  • Influential and assertive communication skills.
  • Excellent leadership skills.
  • Good record-keeping skills.
  • Ability to motivate.
  • Self-confidence.
  • Ability to think outside the box.
  • Problem-solving skills.
  • Conflict-management skills.

About the company

TransMedics makes the Organ Care System (OCS), a portable device that keeps donor organs alive outside the body using warm, oxygenated perfusion with continuous viability monitoring. The system circulates warmed, nutrient-rich blood through an organ, enabling assessment in near-physiological conditions and supports FDA-approved preservation and assessment for hearts, lungs, and livers. It earns revenue by selling the OCS consoles, selling single-use disposable sets for procedures, and offering the National OCS Program, which provides end-to-end organ retrieval, logistics, and clinical support. Its goal is to increase transplant chances and organ utilization by improving preservation, assessment, and logistics across centers.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Andover, Massachusetts

Founded

1998

Get referred to TransMedics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 21% to $189.9 million, and guidance increased to $737-$757 million.
  • FDA approved ENHANCE Heart and DENOVO Lung IDEs in January-February 2026, advancing next-generation trials.
  • PAD Aviation closed July 6, 2026, opening pan-European transplant logistics contracts.

What critics are saying

  • Judge Sorokin partially denied dismissal July 21, 2026, forcing discovery in the fraud case.
  • CHOPS and kidney development burn cash while gross margin slipped to 60% in Q2 2026.
  • A bad ENHANCE or DENOVO safety signal in 2026-2027 would damage OCS credibility.

What makes TransMedics unique

  • FDA-approved OCS remains the only U.S. warm-perfusion platform for hearts, lungs, and livers.
  • The National OCS Program bundles surgeons, logistics, aircraft, and disposables into a sticky ecosystem.
  • PAD Aviation extends TransMedics' logistics moat into Europe, copying the U.S. NOP playbook.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Short Term Disability
  • Long Term Disability
  • Health Savings Account/Flexible Spending Account
  • Dependent Care Flexible Spending Account
  • 401(k) Plan
  • Pet insurance
  • Employee Stock Purchase Plan
  • Wellness Program

Growth & Insights and Company News

6 month growth

2%

1 year growth

2%

2 year growth

2%
Yahoo Finance
Oct 1st, 2026
TransMedics director buys $109K in stock amid 30% yearly decline

David Weill, a director at TransMedics Group, purchased 1,336 shares of common stock for approximately $109,000 on 11 September 2026, according to an SEC Form 4 filing. The purchase increased his direct holdings by 9% to 16,392 shares, valued at roughly $1.4 million. The transaction occurred as the stock recorded a one-year return of -30%. TransMedics, a commercial-stage medical technology company with a market capitalisation of $2.7 billion, develops the Organ Care System, a portable device that preserves and monitors donor organs for transplantation. The company reported trailing twelve-month revenues of $668.5 million and net income of $151.7 million. Management has guided for 22%-25% sales growth in 2026 as it expands internationally and develops new platforms.

Yahoo Finance
Sep 15th, 2026
TransMedics and SoFi stocks fall 28% and 34% but show strong buying potential

TransMedics Group and SoFi Technologies have declined 28% and 34% respectively over the past year, presenting potential buying opportunities despite broader market strength driven by tech giants. TransMedics, which developed the Organ Care System for transplants, faces near-term headwinds. Second-quarter revenue grew 21% year over year to $189.9 million, marking a slowdown from recent quarters. Adjusted earnings per share fell 52% to $0.44. However, the company is investing in expansion initiatives, including potential kidney transplant approval and a logistics network for greater control over the organ transplant cycle. These investments are pressuring current profits but could drive future growth. The OCS technology maintains organ temperature and blood supply during transport, addressing limitations of traditional cold storage methods. With a large addressable market remaining, the stock may offer value at current levels.

PR Newswire
Aug 4th, 2026
TransMedics reports 21% revenue growth to $190M in Q2 2026, raises guidance despite margin pressure

TransMedics Group reported second quarter 2026 revenue of $189.9 million, a 21% increase from $157.4 million in the prior year period. The growth was driven primarily by increased utilisation of the company's Organ Care System, particularly in liver and heart transplants through its National OCS Programme, as well as logistics services revenue. Gross margin decreased to 60% from 61% year-over-year, reflecting a higher mix of service revenue and temporary product-cost factors. Net income fell to $14.7 million, or $0.41 per diluted share, compared to $34.9 million, or $0.92 per share, in the second quarter of 2025. The company raised the low end of its full-year 2026 revenue guidance to a range of $737 million to $757 million, representing approximately 22% to 25% growth. TransMedics develops portable extracorporeal warm perfusion technology for donor organ transplantation.

MarketScreener
Jul 6th, 2026
TransMedics invests in PAD Aviation to build Europe-wide organ transplant air logistics network

TransMedics Group has completed a strategic investment in PAD Aviation service GmbH, a Germany-based private aviation operator. The deal aims to establish a dedicated organ transplantation air logistics network across Europe, replicating TransMedics' OCS NOP model from the US. PAD Aviation, founded in 2006, operates from a 24/7 hub in Paderborn, Germany. The company maintains a fleet of nine Embraer Phenom 300 aircraft and employs over 40 pilots, holding a valid EASA Air Operator Certificate. TransMedics develops portable extracorporeal warm perfusion technology for preserving and assessing donor organs. The investment supports the company's efforts to expand adoption of its OCS perfusion technology and create a pan-European organ transport logistics network across the European Union.

Yahoo Finance
Jul 2nd, 2026
TD Cowen sets $120 target on TransMedics, sees 77% upside on transplant growth

TransMedics Group has received a 'Buy' rating from TD Cowen with a $120 price target, implying 77% upside from its last close. The firm cited growing US transplant activity in heart, liver and lung procedures as a key driver for the company's Organ Care System technology and logistics business. Monthly US transplant data showed volumes rose approximately 5% year-over-year in the second quarter of 2026. TransMedics generated $173.9 million in total revenue in the first quarter of 2026, up 21% year-over-year, with product revenue reaching $108 million and service revenue contributing $66 million. The company ended the quarter with $461.7 million in cash and cash equivalents. Shares closed up 2% on Wednesday and gained further in after-hours trading.